Arcutis Biotherapeutics
Update in progressARQT (NasdaqGS)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Arcutis Biotherapeutics, Inc. is a biopharmaceutical company focused on dermatology therapies. Its lead product, ZORYVE, is a topical roflumilast cream approved for plaque psoriasis and atopic dermatitis, with ZORYVE foam under development for seborrheic dermatitis and scalp and body psoriasis. ARQ-234 is a fusion protein acting as a checkpoint agonist of the CD200 receptor. The company, renamed in 2019, was founded in 2016 and is headquartered in Westlake Village, California.
Company score
- Sentiment
- 0.50
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.44
- Governance
- 0.07
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.14
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.32
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Sort by
Order by
Timeframe
No news articles are available for this company yet.
Unable to load company news.
Loading more news
You're all caught up!